Getting it into your agent
One page per mod, every tool's command on it. A separate URL per tool would split the same page into five that compete with each other.
npx agentmods add skills/choxos/biostatagent/group-sequential-methodsnpx skills add choxos/BiostatAgent --skill group-sequential-methodsgit clone --depth 1 https://github.com/choxos/BiostatAgentWrote this? Show the measurements
A badge with what this costs and how it scanned, read live from this page, so it follows the numbers instead of freezing them. Markdown for a README, HTML for a documentation site or a project page.
[](https://agentmods.dev/skills/choxos/biostatagent/group-sequential-methods)<a href="https://agentmods.dev/skills/choxos/biostatagent/group-sequential-methods"><img src="https://agentmods.dev/badge/skills/choxos/biostatagent/group-sequential-methods.svg" alt="Measured on agentmods" height="20"></a>What it costs to keep this loaded
Counted locally with the o200k_base tokenizer, which is exact for GPT models; Claude uses its own tokenizer and its counts differ. Treat this as one consistent yardstick across the catalogue rather than a bill. Prices are per million input tokens.
| Model | Per session | Once invoked |
|---|---|---|
| Fable 5 | $0.00034 | $0.02444 |
| Opus 5 | $0.00017 | $0.01222 |
| Sonnet 5 | $0.00007 | $0.00489 |
| Haiku 4.5 | $0.00003 | $0.00244 |
Grade A, and why
group-sequential-methods scanned grade A with 0 findings against 26 rules in 11 categories — prompt injection, anti-refusal, data exfiltration, privilege escalation, supply chain, agent snooping, system-prompt leakage, SSRF and excessive agency — measured 3d ago.
A static scan of the body, not an audit. Every finding is printed with the line that produced it so you can judge whether it matters here. A mod is markdown that instructs an agent; that is exactly why what it instructs is worth reading.
Nothing flagged
None of the 26 patterns this scan looks for appear in this file: no shell pipes, no recursive deletes, no credential paths, no hidden text, no instruction-override or anti-refusal phrasing, no agent-config snooping. That is not a guarantee, it is the absence of the things that are checkable.
How it starts
The opening of the file, as written. The whole thing — 347 lines — stays where its author put it; the contents beside it link to each section on GitHub.
Group Sequential Methods
When to Use This Skill
- Designing group sequential trials with interim analyses
- Implementing alpha spending functions
- Setting futility stopping rules
- Calculating information fractions
- Using sim_gs_n() for GS simulations
- Integrating with gsDesign2 package
Fundamental Concepts
Group Sequential Design
A group sequential design allows for:
- Early stopping for efficacy: If treatment effect is larger than expected
- Early stopping for futility: If treatment effect is unlikely to reach significance
- Reduced expected sample size: When treatment effect is present
Information Fraction
Information fraction at analysis k:
I_k / I_K = (events at analysis k) / (total planned events)
For time-to-event trials, information ≈ number of events.
Type I Error Spending
The key constraint is that the design controls the overall Type I error at the planned alpha level. Spending functions define cumulative alpha spending over information time, and boundaries are derived using the joint distribution of sequential test statistics. They are not obtained by simply assigning independent nominal alpha levels to each look.
Alpha Spending Functions
O'Brien-Fleming (OBF)
Properties:
- Conservative at early analyses
- Nearly full alpha at final analysis
- Difficult to stop early
- Maintains nominal Type I error
Formula:
α*(t) = 2 - 2Φ(z_{α/2} / √t)
When to Use:
- Want maximum power at final analysis
- Early efficacy stopping unlikely
- Regulatory preference for conservative early bounds
Pocock
Properties:
- Equal spending at each analysis
- Easier to stop early
- Inflated final alpha
- Lower power at final analysis
Formula:
α*(t) = α × log(1 + (e-1)t)
When to Use:
- Early stopping is a priority
- Treatment effect expected to be large
- Willing to sacrifice final analysis power
Hwang-Shih-DeCani (HSD)
Properties:
- Flexible family indexed by γ
- γ = -4: Similar to OBF
- γ = 1: Similar to Pocock
- γ = 0: Linear (Pocock-like)
What this file has done since we first saw it
Hashed on every crawl. A supply-chain change to an agent config is a question of when, not whether, so the history is kept rather than the latest state alone.
- 3d ago First seen · 347 lines · 34 tokens per session scan A 20c699a4513a
group-sequential-methods is a skill published in the GitHub repository choxos/BiostatAgent (11 stars, last pushed 3mo ago), licensed MIT. It adds 34 tokens to every session and 2,444 once invoked, about $0.0002 per session on Opus 5. A static security scan graded it A with 0 findings. No closer match exists in the catalogue, so it is treated as the original; first seen 2026-08-30.
Other skills, from other repositories
biomcp
Search and retrieve biomedical data - genes, variants, clinical trials, diagnostic tests, articles, drugs, diseases, pathways, proteins, adverse events, pharmacogenomics, and phenotype-disease matching. Use for gene function, variant pathogenicity, trials, diagnostics, drug safety, pathway context, disease workups…
clinical-trials-search
Search ClinicalTrials.gov with natural language queries. Find clinical trials, enrollment, and outcomes using Valyu semantic search.
omop-migration-mapper
Generates a mapping schema to transform any EMR/healthcare database to OHDSI OMOP CDM format. Use when the user needs to map source healthcare data tables to OMOP using pyomop-migrate, extract a source database schema, define column mappings, resolve concept lookups, validate data quality, and produce a…
lifesciences-clinical
Queries clinical databases (Open Targets, ClinicalTrials.gov) via curl for target-disease associations, target tractability assessment, and clinical trial discovery. This skill should be used when the user asks to "validate drug targets", "find clinical trials", "assess target tractability", "discover disease…
lifesciences-crispr
Validates synthetic lethality claims from CRISPR knockout screens using BioGRID ORCS 5-phase workflow. This skill should be used when the user asks to "validate synthetic lethality", "query CRISPR essentiality data", "find gene dependencies", "compare cell line screens", or mentions BioGRID ORCS, gene knockout data…
lifesciences-graph-builder
Orchestrates life sciences APIs to build knowledge graphs using the Fuzzy-to-Fact protocol, combining MCPs for nodes and curl for edges, then persisting to Graphiti. This skill should be used when the user asks to "build knowledge graphs", "find biological connections", "explore drug repurposing", "validate drug…